Serum prostate-specific antigen (PSA) is an effective diagnostic tool for detection of prostate cancer (CaP) at an early and potentially curable stage, but specificity is low. Studies have shown that the proportion of serum PSA complexed with alpha-1-antichymotrypsin (ACT) is higher in men with CaP than in men with benign prostate disease. We developed a novel immunoassay for complexed PSA base...

Part 1 of a two-part discussion of Prostate Cancer from an underwriting perspective, covers the epidemiology and screening for prostate cancer. Included is a "Primer on Screening Tests" that discusses problems with digital rectal exam (DRE) and prostate specific antigen (PSA) as screening tests. Approaches to enhancing the use of PSA for screening including age and race specific ranging, PSA de...

We compared prostate-specific antigen (PSA) assay systems [i.e., free PSA (f-PSA) and the corresponding total PSA (t-PSA) assay] from four different manufacturers as well as the f-PSA/t-PSA ratios with regard to their ability to discriminate between benign prostate hyperplasia (BPH) and prostate cancer (PCA). ROC analysis showed similar areas under the curves (AUCs) with different assay systems...

In a recent paper entitled “Simulation optimization of PSAthreshold based prostate cancer screening policies” [2], we presented a prostate-specific antigen (PSA) screening policy designed by a heuristic simulation-optimization procedure based on a genetic algorithm (GA). A key part of this procedure involved simulating the natural history of prostate cancer. Because we examined PSA-threshold ba...

Background: Prostate cancer has been reported as a worldwide important kind of cancer and the second most common cause of cancer-related mortality among men. Prostate-specific antigen (PSA) serum level is one of the most important markers of prostate cancer diagnosis. While PSA level helps predict the risk of prostate cancer development, researchers still looking for ways to increase the accura...

Introduction The Use of PSA for Early Detection of Prostate Cancer The Use of PSA for Pretreatment Staging of Prostate Cancer The Use of PSA in the Posttreatment Management of Prostate Cancer Methods Used in Best Practice Policy Development References PSA Best Practice Policy Task Force Prostate cancer is the most common form of noncutaneous cancer in men in the United States. Despite its preva...

BACKGROUND The serum prostate specific antigen for the early detection and screening for prostate cancer are very common used among physicians as the best screening tool for prostate cancer. The result of prostate specific antigen levels discriminates whether or not a prostate biopsy should be performed. The lack of specificity is a limitation of PSA as tumor marker, increased PSA concentration...

Like other countries, Japan is recording a rapid increase in the incidence of prostate cancer. The use of serum PSA (prostate specific antigen) measurement as a blood marker for prostate cancer has become widespread. Higher levels of PSA are associated with a higher probability of a diagnosis of prostate cancer. Needle biopsies detect prostate cancer in 20–30% of cases with PSA levels of 4.1–10...

El antígeno específico de próstata (PSA, del inglés, Prostate Specific Antigen) es una glicoproteína producida por la próstata, y el marcador tumoral mayor uso. Sin embargo, su baja especificidad para diferenciar entre cáncer otras alteraciones no malignas, como hipertrofia benigna (HBP) prostatitis aguda, limitan utilidad diagnóstica.

Patients with advanced prostate cancer frequently have a poor prognosis as a result of metastasis. The serum prostate-specific antigen (PSA) test is widely used for the diagnosis of prostate cancer. The enzymatic activity of PSA may be involved in the invasion of prostate cancer. We set out to determine the prevalent form of PSA in human prostate adenocarcinoma samples by ELISA and Western blot...